Euronews Debates | How can Europe shape the future of biosimilar medicines?

With the cost of healthcare rising in Europe, experts are considering how to build the sustainable healthcare system of the future.

Currently, around one third of healthcare spending goes to biologics, drugs that use living organisms as ingredients. These medicines target parts of your immune system to treat disease and are particularly effective for treating diseases such as arthritis.

But while they are effective and in ever-increasing demand, they are expensive. IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, found that biological products accounted for 34% of medical spending in Europe in 2021, for a total cost of 78. 6 billion euros.

With healthcare systems under increasing financial strain, especially in the wake of the COVID-19 pandemic, cheaper alternatives may be considered welcome.

Biosimilar drugs are very similar to biologics in terms of structure, biological activity and efficacy, but they are much cheaper to develop. This is because they are often developed on the basis of a successful biologic once its patent has expired.

For example, € 5.7 billion was saved in Europe in 2021 by switching to biosimilars and generics according to this IQVIA report.

Euronews is gathering a panel of experts, industry leaders and key players in Brussels to discuss the challenges of creating a sustainable biosimilar market system.

On November 15, from 1530 CET, our live panel in the European Parliament will discuss key issues such as:

  • What forces are shaping the biosimilar market in Europe?

  • What is being done currently and what will need to be addressed in the future to create a uniform and sustainable system?

  • Why has there been a slow adoption of biosimilars in some countries?

  • What does all this mean for patients and for the European healthcare system as a whole?

Our expert speakers will consist of:

  • Tomislav SokolMEP, Group of the European People’s Party and member of the EU special committee on the COVID-19 pandemic: lessons learned and recommendations for the future
  • Adrian van den HovenDirector General, Medicines for Europe
  • Ian HenshawGlobal Head of Biosimilars, Biogen
  • Luisa AvedanoCEO, European Federation of Crohn’s and Ulcerative Colitis Associations

The debate will take place during World Biosimilar Week. It is the third annual social media campaign to encourage people to share their stories, resources and information on social media with the hashtag #GlobalBiosimilarsWeek.

Ask your questions, join the debate and let us know what you think. Our guests are ready to respond!